A new study is offering encouraging news for people living with BRAF V600E-mutant metastatic colorectal cancer (mCRC), a subtype of colorectal cancer (CRC) that can be especially difficult to treat. Results from the phase III BREAKWATER clinical trial found that a targeted treatment combination using encorafenib (Braftovi), cetuximab (Erbitux), and chemotherapy significantly improved progression-free survival […]

A recent clinical trial is offering hope for people living with a specific type of metastatic colorectal cancer (mCRC). Researchers found that combining immunotherapy with chemotherapy and targeted therapy may help patients live longer without their cancer growing or spreading compared to immunotherapy alone. The findings come from the phase III COMMIT trial, which was […]